Inuvair (Formoterol Fumarate Dihydrate, Beclometasone Dipropionate Anhydrous)

Formoterol, a long‑acting β2‑adrenergic agonist, relaxes airway smooth muscle by stimulating β2 receptors, providing sustained bronchodilation. Beclometasone, an inhaled glucocorticoid, binds glucocorticoid receptors to suppress inflammatory gene expression, decreasing airway swelling and mucus production. Together they deliver both bronchodilatory and anti‑inflammatory effects.

The specific dose and inhalation schedule for Inuvair are determined by the prescribing clinician based on the patient’s severity of asthma or COPD, age, and response to therapy. Patients should follow the exact instructions provided on the prescription label and by their healthcare professional.

Safety data for Inuvair in pregnancy and lactation are limited. The product should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss risks and alternatives with their healthcare provider.

To request Inuvair, visit the product page on gnhindia.com, enter the required quantity, and submit the enquiry form. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Inuvair combines a long‑acting β2‑agonist (formoterol) with an inhaled corticosteroid (beclometasone) in a single device, offering both bronchodilation and anti‑inflammatory action. Compared with single‑component inhalers, this fixed‑dose combination can simplify regimens, improve adherence, and provide consistent dosing, though choice of therapy should be individualized by the prescriber.

Store Inuvair at room temperature, below 25 °C (77 °F). Keep the inhaler in its original packaging, protect it from moisture and direct sunlight, and avoid exposing it to extreme temperatures that could affect the stability of the active ingredients.

Inuvair is delivered via inhalation using a metered‑dose inhaler. Patients should prime the device according to the manufacturer’s instructions, exhale fully, place the mouthpiece in the mouth, and inhale slowly and deeply while actuating the inhaler. A spacer may be used to improve drug deposition and reduce oropharyngeal exposure.

Serious adverse events, although rare, include paradoxical bronchospasm, severe allergic reactions such as anaphylaxis, cardiac arrhythmias, pneumonia (particularly in COPD), and systemic effects of corticosteroids like adrenal suppression or reduced bone density with prolonged high‑dose use. Patients should seek immediate medical attention if any of these occur.

Inuvair is contraindicated in patients with a known hypersensitivity to formoterol, beclometasone, or any component of the inhaler. It should also be avoided in individuals who have experienced a severe allergic reaction to other inhaled corticosteroids or β2‑agonists. Clinicians must assess each patient’s medical history before initiating therapy.